What is Mastocytosis?
Mastocytosis is a heterogeneous group of clonal myeloid disorders characterized by pathologic accumulation of abnormal mast cells in the skin and/or extracutaneous organs including bone marrow, liver, spleen, and lymph nodes. 1
Disease Classification
Mastocytosis encompasses three main categories 1:
- Cutaneous mastocytosis - mast cell accumulation limited to the skin
- Systemic mastocytosis (SM) - mast cell infiltration of one or more extracutaneous organs with or without skin involvement
- Mast cell sarcoma - rare aggressive variant
Age-Related Disease Patterns
The disease presents in two distinct age-related patterns with fundamentally different clinical behavior 1:
Pediatric-Onset Mastocytosis
- Typically diagnosed before age 2 years (60-80% develop lesions during the first year of life) 1
- Predominantly cutaneous disease with urticaria pigmentosa (UP) being the most common presentation (70-90% of cases) 1
- Variable and often self-limited course - many cases resolve spontaneously by puberty 1, 2
- Less frequently associated with c-kit mutations (only 43% of pediatric cases versus majority of adult cases) 1, 2
- Internal organ involvement is uncommon 1
Adult-Onset Mastocytosis
- Generally presents with systemic findings that increase in extent and severity over time 1, 2
- Systemic mastocytosis is the most common form diagnosed in adults 1
- Associated with KIT D816V mutations in the majority of cases 1, 3
- Chronic progressive course with potential for advanced disease 1
Clinical Manifestations
Symptoms arise from two primary mechanisms 1:
Mast Cell Mediator Release (occurs in >60% of cases)
- Cutaneous: flushing, pruritus, urticaria, angioedema 3
- Gastrointestinal: abdominal cramping, diarrhea (up to 40% in children, 80% in systemic disease), nausea, vomiting, malabsorption 3
- Cardiovascular: hypotension, tachycardia, syncope 3
- Respiratory: wheezing, dyspnea 3
- Neuropsychiatric: headache, cognitive difficulties 3
- Anaphylaxis - potentially life-threatening 3
Tissue Infiltration
- Organ dysfunction from mast cell burden in bone marrow, liver, spleen, or gastrointestinal tract 1
Pathophysiology
The disease results from clonal growth of abnormal mast cells, most commonly associated with activating mutations in the KIT gene (particularly KIT D816V in adults) 1, 3. This receptor tyrosine kinase mutation drives mast cell proliferation and survival 1.
Diagnostic Approach
Referral to specialized centers with expertise in mastocytosis is strongly recommended given the complexity and rarity of the disease 1, 3.
WHO Diagnostic Criteria for Systemic Mastocytosis
Diagnosis requires 1 major + 1 minor criterion, OR ≥3 minor criteria 1, 3:
Major Criterion:
- Multifocal, dense infiltrates of ≥15 mast cells in aggregates in bone marrow or extracutaneous organs 1, 3
Minor Criteria:
- KIT D816V or other activating KIT mutation detected 1, 3
- Aberrant expression of CD25 ± CD2 on mast cells 1, 3
- Persistently elevated baseline serum tryptase >20 ng/mL (in absence of associated myeloid neoplasm) 1, 3
Prognosis
Prognosis varies dramatically by subtype and age of onset 1, 3:
- Pediatric cutaneous mastocytosis: excellent prognosis with frequent spontaneous resolution 1, 2
- Indolent systemic mastocytosis (ISM): near-normal life expectancy with median survival of 301 months 3
- Aggressive systemic mastocytosis (ASM): significantly worse prognosis with median survival of only 41 months 3
Critical Clinical Pitfalls
Never extrapolate adult treatment approaches to pediatric mastocytosis - the diseases differ fundamentally in presentation, prognosis, and genetic pathophysiology 1, 2. Antiproliferative agents carry vastly different long-term toxicity concerns in children versus adults 1, 2.
Multidisciplinary collaboration is essential, particularly with allergists for anaphylaxis management, anesthesiologists for invasive procedures, and high-risk obstetricians for pregnancy 1.